<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938389</url>
  </required_header>
  <id_info>
    <org_study_id>2018H0061</org_study_id>
    <secondary_id>K23DK117041</secondary_id>
    <nct_id>NCT03938389</nct_id>
  </id_info>
  <brief_title>The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans</brief_title>
  <official_title>The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism Among African Americans: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to examine the impact of the Renin-Angiotensin-Aldosterone System
      (RAAS) blockade with medications (valsartan) or RAAS and neprilysin inhibition
      (valsartan/sacubitril) vs. placebo on changes in blood sugar and insulin secretion from the
      pancreas over 26 weeks assessed with glucose clamp studies among African Americans (AAs) with
      impaired glucose tolerance.

      The investigators hypothesize that combined RAAS/neprilysin inhibition will lead to greater
      improvement in insulin release from the pancreas and improved blood sugar compared to RAAS
      inhibition alone among AAs with impaired glucose tolerance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 25, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized prospective controlled clinical trial with three parallel arms, no crossover.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinding</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to 26 weeks in β-cell function (first-phase insulin secretion)</measure>
    <time_frame>26 weeks</time_frame>
    <description>β-cell function will be assessed by first-phase insulin secretion, calculated as the mean insulin concentration (uIU/mL) over 10 minutes during the hyperglycemic clamp.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Central Aortic Pressure (mmHg) from Baseline to 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
    <description>Central Aortic Pressure, measured via a non-invasive method using the SphygmoCor XCEL device, in mmHg.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>PreDiabetes</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Obesity</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan 160 mg twice daily for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sacubitril/Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sacubitril/Valsartan (97/103 mg) twice daily for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (+/- amlodipine 2.5-5 mg twice daily if high blood pressure)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan Tab 97-103 MG</intervention_name>
    <description>Participants will take Sacubitril-Valsartan for 26 weeks</description>
    <arm_group_label>Sacubitril/Valsartan</arm_group_label>
    <other_name>Entresto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg</intervention_name>
    <description>Participant will take Valsartan for 26 weeks</description>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  African Americans aged 18-65 years old with a history of impaired fasting glucose,
             impaired glucose tolerance, hemoglobin A1c 5.7-6.4% or other risk factors for diabetes
             including metabolic syndrome, family history of type 2 diabetes in the parents or
             siblings or history of gestational diabetes will be invited to attend a formal
             screening visit. Participants with impaired glucose tolerance defined as 2-hour plasma
             glucose 140-199 mg/dl after a fasting 75-g oral glucose tolerance test and who meet
             other enrollment criteria will be enrolled.

        Exclusion Criteria:

          -  Type 2 Diabetes (American Diabetes Association Criteria)

          -  Hypertension with systolic blood pressure (SBP) &gt; 150 mmHg or diastolic blood pressure
             (DBP) &gt; 100 mmHg or taking anti-hypertensive medications

          -  SBP &lt; 100 mmHg or DBP &lt; 60 mmHg

          -  Pharmacologic treatment with statins, β-Blockers, angiotensin converting enzyme
             inhibitors, angiotensin II receptor blockers, renin inhibitors, and/or
             mineralocorticoid antagonists

          -  Steroid use

          -  Hyperkalemia (Potassium &gt; 5.0 milliequivalent/L)

          -  Abnormal renal function tests: Glomerular Filtration Rate calculated using the Chronic
             Kidney Disease Epidemiology Equation &lt; 60 ml/min/1.73 m²

          -  Treatment with oral hypoglycemic medications,

          -  Use of antipsychotic medications or severe psychiatric disorders (severe mental
             illness)

        Severe Psychiatric Disorders:

          -  Schizophrenia

          -  Paranoid and other psychotic disorders

          -  Bipolar disorders (hypomanic, manic, depressive, and mixed)

          -  Major depressive disorders (single episode or recurrent)

          -  Schizoaffective disorders (bipolar or depressive)

          -  Pervasive developmental disorders

          -  Obsessive-compulsive disorders

          -  Depression in childhood and adolescence

          -  Panic disorder

          -  Post-traumatic stress disorders (acute, chronic, or with delayed onset)

          -  Bulimia Nervosa

          -  Anorexia Nervosa

               -  History of, or planned, bariatric surgery,

               -  Weight loss &gt; 5% over the previous 6 months,

               -  Pregnancy, planning to conceive a child in the next 9 months, or progesterone
                  based contraception and unable to switch to non-progesterone based contraception,

               -  Previous or current diagnosis of cardiac structural and functional abnormalities,
                  history or current diagnosis of heart failure (New York Heart Association classes
                  II-IV), history of myocardial infarction, coronary bypass surgery, or
                  percutaneous coronary intervention during the 6 months prior to screening,

               -  History of angioedema, or known hypersensitivity to study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua J Joseph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State University Wexner Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amber Anaya, BS, CCRC</last_name>
    <phone>(614) 688-6257</phone>
    <email>Amber.Anaya@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Anaya, BS, CCRCLPN</last_name>
      <phone>614-688-6257</phone>
      <email>Amber.Anaya@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua J Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Joshua Joseph, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>African American</keyword>
  <keyword>Black</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Impaired Glucose Tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

